WHAT IS CLAIMED IS:

1. An IGF2 fusion polypeptide, wherein the amino acid sequence of the polypeptide is 100% identical to SEQ ID NO: 34 and 6 amino acids are deleted from the N-terminus of SEQ ID NO: 34.

2. Use of the IGF2 fusion polypeptide of claim 1 in the manufacture of a medicament for treating a muscle or soft-tissue disorder or condition in a subject, wherein a therapeutically effective amount of the polypeptide is to be administered to the subject.

3. The use according to claim 2, wherein the disorder or condition is a muscular dystrophy, a sarcopenia, a cachexia, or a muscle injury.

4. The use according to claim 2, wherein administration increases a muscle regeneration in the subject.

5. The use according to claim 2, wherein administration increases proliferation or promotes survival of a muscle cell.

6. The use according to claim 2, wherein administration increases a regenerative capability of a myoblast in the subject.

7. The use according to claim 6, wherein the regenerative capability is a proliferation, a degree of differentiation, or a cellular survival.

8. The use according to claim 7, wherein increasing a proliferation of the myoblast produces an increase in new myofibers.

9. The use according to any one of claims 2-8, wherein administration increases the number of new muscle fibers per square millimeter of muscle in the subject.

10. The use according to any one of claims 2-8, wherein administration increases a grip strength of the subject.

11. The use according to any one of claims 2-8, wherein administration increases a weight of muscle in the subject.

12. The use according to any one of claims 2-8, wherein administration increases a forelimb force in the subject.

13. The use according to any one of claims 2-8, wherein administration increases a lean body mass of the subject.

14. The use according to any one of claims 2-8, wherein administration increases an appendicular skeletal muscle index of the subject.

15. The use according to any one of claims 2-8, wherein the disorder or condition is a sarcopenia.

16. The use according to any one of claims 2-8, wherein the disorder or condition is a muscular dystrophy.

17. The use according to any one of claims 2-8, wherein the disorder or condition is a result of an obesity, a disease progression, a metabolic disorder, a therapeutic treatment, or a combination thereof.

18. The use according to any one of claims 2-8, wherein the disorder or condition is a cachexia.

19. The use according to claim 17, wherein the metabolic disorder is a diabetes.

20. The use according to any one of claims 2-8, wherein the disorder or condition results from a muscle injury, or a limb immobilization.

21. The use according to claim 16, wherein the muscular dystrophy is a myotonic dystrophy

22. The use according to claim 21, wherein the myotonic dystrophy is Myotonic Dystrophy Type 1 (DM1).

23. The use according to claim 16, wherein the muscular dystrophy is a Limb-girdle muscular dystrophy.

24. The use according to claim 16, wherein the muscular dystrophy is a Becker muscular dystrophy.

25. The use according to claim 16, wherein the muscular dystrophy is an oculopharyngeal muscular dystrophy.

26. The use according to claim 16, wherein the muscular dystrophy is a facioscapulohumeral muscular dystrophy.

27. The IGF2 fusion polypeptide of claim 1, for use in therapy.